

ForPatients

by Roche

Rectal Cancer Rectal Neoplasms

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemotherapy in Participants With Locally Advanced Rectal Cancer

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT05009069 ML43050

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC). The study consists of a safety run-in phase and a randomization phase. Participants enrolled in the safety run-in phase will receive atezolizumab + tiragolumab following nCRT. Upon determination of the safety of the treatment regimen, the study will proceed to the randomization phase. Participants will be randomized in a 1:1 ratio to the atezolizumab + tiragolumab arm or atezolizumab arm.

Hoffmann-La Roche

Sponsor

Phase 2

Phase

NCT05009069 ML43050

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
